Catalyst Event

GSK plc (GSK) · Other

From KEDI Global Longevity Bio Index (KGLB)

3/19/2026, 12:00:00 AM

OtherSentiment: Positive

The US FDA is expected to approve Lynavoy (linerixibat) for PBC-related cholestatic pruritus on March 19, 2026; Medium importance estimated for first-in-class drug approval expected.

Korean Translation

2026년 3월 19일, PBC 환자의 담즙 정체성 소양증 치료제 리나보이(라이너릭시뱃)의 미국 FDA 승인이 예상됨 (최초 치료제 승인에 따른 중간 수준의 영향 예상됨).

Related Recent Events

View Full Timeline